AnBogen Therapeutics, Inc. is focused on precision oncology, developing targeted therapies aimed at addressing unmet medical needs in cancer treatment. The company emphasizes the integration of its research findings with clinical development to create innovative cancer therapies. Their R&D pipeline showcases a commitment to leveraging scientific expertise and extensive experience in drug development, which is crucial for advancing their precision oncology drugs.

The company has recently announced collaborations and funding initiatives to support its drug development efforts. For instance, a collaboration with BeiGene aims to evaluate combination therapy in colorectal cancer, while recent financing rounds have provided significant capital to advance their clinical trials. AnBogen's strategic approach highlights its dedication to transforming the lives of cancer patients through innovative therapeutic solutions.

Taiwan

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs.

Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development. 


Cancer

C523, No.99, Lane 130, Sec. 1, Research Institute Road, Nangang Dist., Taipei 11571, Taiwan(R.O.C.)

AnBogen

Company Details